Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Sobral, Lays M ^a   Sousa, Lucas O ^a   Coletta, Ricardo D ^b   Cabral, Hamilton ^a   Greene, Lewis J ^a   Tajara, Eloiza H ^a   Gutkind, J Silvio ^c   Curti, Carlos ^a   Leopoldino, Andréia M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Cisplatin; EMT; ERK; Head and neck cancer; Invasion; Metastasis; MMP; p53; SET

Indexed keywords

CISPLATIN; CYTOKERATIN; GELATINASE A; GELATINASE B; MESSENGER RNA; MYOSIN HEAVY CHAIN; PHOSPHOPROTEIN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UVOMORULIN; VIMENTIN;

ANALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL CYCLE G1 PHASE; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FLUOROMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MESENCHYME; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TONGUE; UPREGULATION; WESTERN BLOTTING; XENOGRAFT; ZYMOGRAPHY;

MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; HEAD AND NECK NEOPLASMS; HISTONE CHAPERONES; HUMANS; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; MICE, NUDE; NECROSIS; NEOPLASM INVASIVENESS; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896720465     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-32     Document Type: Article

References (46)

1. Adachi Y, Pavlakis GN, Copeland TD. Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem 1994, 269:2258-2262.
2. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996, 271:11059-11062. 10.1074/jbc.271.19.11059, 8626647.
3. Van Kanegan MJ, Adams DG, Wadzinski BE, Strack S. Distinct protein phosphatase 2A heterotrimers modulate growth factor signaling to extracellular signal-regulated kinases and Akt. J Biol Chem 2005, 280:36029-36036. 10.1074/jbc.M506986200, 16129692.
4. Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem 2008, 283:1882-1892. 10.1074/jbc.M709585200, 18042541.
5. Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Polizello AC, Uyemura SA, Tajara EH, Gutkind JS, Curti C. Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling. Mol Cell Biochem 2012, 363:65-74. 10.1007/s11010-011-1158-x, 22143534.
6. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849. 10.1038/sj.onc.1207556, 15077147.
7. Fukukawa C, Shima H, Tanuma N, Okada T, Kato N, Adachi Y, Kikuchi K. The oncoprotein I-2PP2A/SET negatively regulates the MEK/ERK pathway and cell proliferation. Int J Oncol 2005, 26:751-756.
8. Jenkins LM, Durell SR, Mazur SJ, Appella E. p53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis 2012, 33:1441-1449. 10.1093/carcin/bgs145, 3499055, 22505655.
9. Taira N, Yoshida K. Post-translational modifications of p53 tumor suppressor: determinants of its functional targets. Histol Histopathol 2012, 27:437-443.
10. Estanyol JM, Jaumot M, Casanovas O, Rodriguez-Vilarrupla A, Agell N, Bachs O. The protein SET regulates the inhibitory effect of p21(Cip1) on cyclin Ecyclin-dependent kinase 2 activity. J Biol Chem 1999, 274:33161-33165. 10.1074/jbc.274.46.33161, 10551888.
11. Liu GP, Wei W, Zhou X, Zhang Y, Shi HH, Yin J, Yao XQ, Peng CX, Hu J, Wang Q, HL L, Wang JZ. I(2)(PP2A) regulates p53 and Akt correlatively and leads the neurons to abort apoptosis. Neurobiol Aging 2012, 33:254-264. 10.1016/j.neurobiolaging.2010.01.016, 20138402.
12. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011, 192:209-218. 10.1083/jcb.201009059, 3172183, 21263025.
13. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010, 15:117-134. 10.1007/s10911-010-9178-9, 2886089, 20490631.
14. Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, Kaufmann AM, Albers AE. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One 2011, 6:e16466. 10.1371/journal.pone.0016466, 3029362, 21304586.
15. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91:325-334. 10.1016/S0092-8674(00)80416-X, 9363941.
16. Pinho AV, Rooman I, Real FX. p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle 2011, 10:1312-1321. 10.4161/cc.10.8.15363, 21490434.
17. Garavello W, Maggioni D, Nicolini G, Motta L, Tredici G, Gaini R. Association between metalloproteinases 2 and 9 activity and ERK1/2 phosphorylation status in head and neck cancers: an ex vivo study. Oncol Rep 2010, 24:10731078.
18. Ghosh M, Song X, Mouneimne G, Sidani M, Lawrence DS, Condeelis JS. Cofilin promotes actin polymerization and defines the direction of cell motility. Science 2004, 304:743-746. 10.1126/science.1094561, 15118165.
19. Li R, Doherty J, Antonipillai J, Chen S, Devlin M, Visser K, Baell J, Street I, Anderson RL, Bernard O. LIM kinase inhibition reduces breast cancer growth and invasiveness but systemic inhibition does not reduce metastasis in mice. Clin Exp Metastasis 2013, 30:483-495. 10.1007/s10585-012-9553-6, 23239465.
20. Zhang H, Ghai P, Wu H, Wang C, Field J, Zhou GL. Mammalian adenylyl cyclase-associated protein 1 (CAP1) regulates cofilin function, the actin cytoskeleton, and cell adhesion. J Biol Chem 2013, 288:28306.
21. Lee S, Helfman DM. Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J Biol Chem 2004, 279:18851891.
22. Qian HL, Peng XX, Chen SH, Ye HM, Qiu JH. p62 Expression in primary carcinomas of the digestive system. World J Gastroenterol 2005, 11:17881792.
23. Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 2009, 137:1001-1004. 10.1016/j.cell.2009.05.023, 19524504.
24. Nezis IP, Stenmark H. p62 at the interface of autophagy, oxidative stress signaling, and cancer. Antioxid Redox Signal 2012, 17:786-793. 10.1089/ars.2011.4394, 22074114.
25. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011, 30:2504-2513. 10.1038/onc.2010.622, 3107340, 21297667.
26. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, Stahelin RV, Perrotti D, Ogretmen B. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 2013, 5:105-121. 10.1002/emmm.201201283, 3569657, 23180565.
27. Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti D. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 2013, 122:19231934.
28. Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N, Bachs O. The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem 2003, 278:1158-1164. 10.1074/jbc.M207497200, 12407107.
29. Madeira A, Pommet JM, Prochiantz A, Allinquant B. SET protein (TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain. FASEB J 2005, 19:1905-1907.
30. Ten Klooster JP, Leeuwen I, Scheres N, Anthony EC, Hordijk PL. Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J 2007, 26:336-345. 10.1038/sj.emboj.7601518, 1783461, 17245428.
31. Lam BD, Anthony EC, Hordijk PL. Cytoplasmic targeting of the protooncogene SET promotes cell spreading and migration. FEBS Lett 2013, 587:111-119. 10.1016/j.febslet.2012.11.013, 23195690.
32. Almeida LO, Goto RN, Pestana CR, Uyemura SA, Gutkind S, Curti C, Leopoldino AM. SET overexpression decreases cell detoxification efficiency: ALDH2 and GSTP1 are downregulated, DDR is impaired and DNA damage accumulates. FEBS J 2012, 279:4615-4628.
33. Leung JW, Leitch A, Wood JL, Shaw-Smith C, Metcalfe K, Bicknell LS, Jackson AP, Chen J. SET nuclear oncogene associates with microcephalin/MCPH1 and regulates chromosome condensation. J Biol Chem 2011, 286:21393-21400. 10.1074/jbc.M110.208793, 3122199, 21515671.
34. Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Sobral LM, Uyemura SA, Tajara EH, Silvio Gutkind J, Curti C. SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification. Oral Oncol 2012, 48:1106-1113. 10.1016/j.oraloncology.2012.05.014, 22739068.
35. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007, 117:2408-2421. 10.1172/JCI31095, 1950458, 17717597.
36. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013, 123:4144-4157. 10.1172/JCI68951, 3784537, 23999433.
37. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG, Carey TE. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003, 25:654-661. 10.1002/hed.10274, 12884349.
38. Itoh T, Terazawa R, Kojima K, Nakane K, Deguchi T, Ando M, Tsukamasa Y, Ito M, Nozawa Y. Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells. Free Radic Res 2011, 45:1033-1039. 10.3109/10715762.2011.591391, 21682664.
39. Casares C, Ramírez-Camacho R, Trinidad A, Roldán A, Jorge E, García-Berrocal JR. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. Eur Arch Otorhinolaryngol 2012, 269:2455-2459. 10.1007/s00405-012-2029-0, 22584749.
40. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, Zacksenhaus E. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011, 10:1563-1570. 10.4161/cc.10.10.15703, 21502814.
41. Groblewska M, Siewko M, Mroczko B, Szmitkowski M. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol 2012, 50:12-19.
42. Cardinali M, Pietraszkiewicz H, Ensley JF, Robbins KC. Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int J Cancer 1995, 61:98-103. 10.1002/ijc.2910610117, 7705939.
43. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012, 9:671-675. 10.1038/nmeth.2089, 22930834.
44. Sobral LM, Bufalino A, Lopes MA, Graner E, Salo T, Coletta RD. Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A. Oral Oncol 2011, 47:840-846. 10.1016/j.oraloncology.2011.06.011, 21727023.
45. Neumann-Jensen B, Holmstrup P, Pindborg JJ. Smoking habits of 611 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol 1977, 43:410-415. 10.1016/0030-4220(77)90328-0, 265045.
46. Klemencic I, Carmona AK, Cezari MH, Juliano MA, Juliano L, Guncar G, Turk D, Krizaj I, Turk V, Turk B. Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase. Eur J Biochem 2000, 267:5404-5412. 10.1046/j.1432-1327.2000.01592.x, 10951198.